The interplay between metabolic syndrome (MetS) and heart failure (HF) is intricate. Population studies show that MetS confers an increased risk to develop HF and this effect is mediated by insulin resistance (IR). However, obesity, a key component in MetS and common partner of IR, is protective in patients with established HF, although IR confers an increased risk of dying by HF. Such phenomenon, known as "obesity paradox," accounts for the complexity of the HF-MetS relationship. Because IR impacts more on outcomes than MetS itself, the former may be considered the actual target for MetS in HF patients.
Metabolic Syndrome in Heart Failure: Friend or Foe? / Arcopinto, M.; Schiavo, A.; Salzano, A.; Bossone, E.; D'Assante, R.; Marsico, F.; Demelo-Rodriguez, P.; Baliga, R. R.; Cittadini, A.; Marra, A. M.. - In: HEART FAILURE CLINICS. - ISSN 1551-7136. - 15:3(2019), pp. 349-358. [10.1016/j.hfc.2019.02.004]
Metabolic Syndrome in Heart Failure: Friend or Foe?
Arcopinto M.;Salzano A.;Bossone E.;D'Assante R.;Marsico F.;Cittadini A.;Marra A. M.
2019
Abstract
The interplay between metabolic syndrome (MetS) and heart failure (HF) is intricate. Population studies show that MetS confers an increased risk to develop HF and this effect is mediated by insulin resistance (IR). However, obesity, a key component in MetS and common partner of IR, is protective in patients with established HF, although IR confers an increased risk of dying by HF. Such phenomenon, known as "obesity paradox," accounts for the complexity of the HF-MetS relationship. Because IR impacts more on outcomes than MetS itself, the former may be considered the actual target for MetS in HF patients.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
